Physician profile
David A Moore
NPI 1710177274
$10,397.09
in general payments reported to CMS, 2019-2025
12 companies · $186 in 2025
The $186 reported for 2025 was less than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $8,457 · 2020: $276 · 2021: $196 · 2022: $657 · 2023: $226 · 2024: $399 · 2025: $186.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $563 · Entertainment: $248.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $563.06 |
| Entertainment | $248.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $8,243.81 | 2019-2025 | Precision 1, Precision7 |
| Optos, INC. | $1,027.78 | 2019-2024 | Panoramic Ophthalmoscope, Oct Ophthalmoscope, Nfc-700 |
| Coopervision INC. | $298.14 | 2019-2025 | Misight Contact Lens, Myday Contact Lens, Clariti Contact Lens |
| Bausch & Lomb Americas INC. | $206.11 | 2022-2025 | Infuse, Miebo, Xiidra |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $181.85 | 2019-2020 | |
| Oyster Point Pharma, INC. | $158.66 | 2022-2024 | Tyrvaya |
| Maculogix, INC. | $81.53 | 2019-2020 | |
| Sun Pharmaceutical Industries INC. | $77.88 | 2021-2025 | |
| Abb Con-Cise Optical Group LLC | $58.84 | 2022 | |
| Kala Pharmaceuticals, INC. | $23.42 | 2021 | |
| Allergan, INC. | $21.54 | 2021 | |
| Novartis Pharmaceuticals Corporation | $17.53 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Moore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.